Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
QN-302 by Qualigen Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
QN-302 is under clinical development by Qualigen Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...
QN-302 by Qualigen Therapeutics for Prostate Cancer: Likelihood of Approval
QN-302 is under clinical development by Qualigen Therapeutics and currently in Phase I for Prostate Cancer. According to GlobalData, Phase...
QN-302 by Qualigen Therapeutics for Sarcomas: Likelihood of Approval
QN-302 is under clinical development by Qualigen Therapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I...
QN-302 by Qualigen Therapeutics for Solid Tumor: Likelihood of Approval
QN-302 is under clinical development by Qualigen Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
QN-302 by Qualigen Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
QN-302 is under clinical development by Qualigen Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...